UK begins H5N1 human vaccine trials

Bird flu vaccines for people have mostly lived in preparedness plans, not in real-world mass trials. That is what changed in late April. Moderna has started a UK-led phase 3 study of an H5 avian flu vaccine, with thousands of adults set to get either the shot or placebo in Britain and the US. The point is simple — build evidence before H5N1 becomes a virus that spreads well between people, not after. ### What actually started? A large phase 3 trial started in the UK on April 22, 2026, for Moderna’s mRNA-1018 vaccine against influenza A(H5N1). The study plans to enroll about 4,000 adults age 18 and older, with roughly 75% of them — around 3,000 people — recruited at UK sites and the rest in the US. Participants get two doses, on day 1 and day 22, or placebo. (nihr.ac.uk) ### Why the UK? The UK is using this as a test of its faster vaccine-trial machinery as much as a test of the vaccine itself. The study is running through the UK Vaccine Innovation Pathway, and officials are bragging — fairly — that the first participant was enrolled in less than half the government’s 150-day setup target. There are 26 UK sites, including community clinics, not just big hospital centers. (nihr.ac.uk) ### What is this vaccine trying to do? This is an mRNA vaccine aimed at H5, the bird flu subtype that has hammered wild birds and poultry and has kept jumping into mammals. The trial is mainly asking two things: is the shot safe, and does it generate a strong immune response against currently circulating and potentially emerging H5N1 strains. It is not a sign that a human H5N1 pandemic has begun. It is a sign that health systems no longer want to wait for that moment to do the homework. (nihr.ac.uk) ### Why now? Because H5N1 is no longer just a bird problem. In the US, the virus has spread through dairy cattle as well as poultry, and human infections have shown up sporadically in people with animal exposure. CDC still says the current public-health risk is low, but the surveillance posture is active because the virus keeps finding new mammal hosts. (nihr.ac.uk) ### What made people more uneasy this week? Two things. First, a new paper from California dairy farms found infectious H5N1 virus in milking-parlor air and in wastewater streams, with viral RNA also detected in cows’ exhaled breath. That matters because it suggests more routes of exposure on farms than simple contact with visibly sick animals. (cdc.gov) ### And the cat case? CDC published serologic evidence on May 7 showing one asymptomatic veterinary worker in Los Angeles County had H5N1 infection after occupational exposure to an infected domestic cat. The report says cat-to-human transmission had not been documented before. That does not mean cats are suddenly a major driver of spread, but it does widen the list of situations health officials have to take seriously. (journals.plos.org) ### Does this mean a pandemic is near? No — and that distinction matters. H5N1 still does not spread easily from person to person. The reason this trial matters is more boring and more important: vaccine platforms work best when regulators, manufacturers, and trial networks have already practiced on the exact kind of threat they might face. Basically, this is rehearsal with a pathogen that keeps moving closer to the human world. (cdc.gov) ### Bottom line? The UK has not declared an emergency. It has done something smarter. It started a big human vaccine trial while H5N1 is still mostly an animal outbreak, because once a flu virus learns the human trick, the window to prepare gets very small. (nihr.ac.uk) (cdc.gov)